Connect with us

Covid-19

The Economics of Covid Vaccines Business and the Poor

Published

on

While a majority of the world’s population and poor nations in Africa are still longing for the first Covid-19 shot, the demand for booster shots by advanced economies   have made manufacturing shots a good opportunity for the pharmaceutical industry. This is bad news for the rest of the world who are still trying to get the first shot.

The mutation of the Covid -19 virus has decreased the  efficacy of initial Covid vaccines. However,  for the drug companies that have spent billions of dollars developing vaccines, it’s a once-in-a-lifetime business opportunity as more booster shots can be produced.

Recent studies on vaccine effectiveness have led to a run of orders for boosters in recent weeks. The U.S. will start distributing extra shots beginning Sept. 20th, and expects to roll out about 100 million doses in the coming months. Shortening the window before a third dose from eight to as little as five months was being discussed, President Joe Biden said last week. The U.K. last week ordered 35 million more doses of the Pfizer Inc. vaccine to supplement earlier shots. In Israel, anyone over 30 is already eligible for a booster.

In Africa, a majority of the nations are still waiting for the first shot.

Trending

Sign up for our Newsletter

Enter your email and stay on top of things,

Subscribe!